Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:alsoKnownAs |
gptkb:capivasertib
|
| gptkbp:ATCCode |
L01EX18
|
| gptkbp:CASNumber |
1032350-13-2
|
| gptkbp:clinicalTrialPhase |
Phase II
|
| gptkbp:developedBy |
gptkb:Merck_&_Co.
|
| gptkbp:hasMolecularFormula |
C25H21ClN4O2S
|
| https://www.w3.org/2000/01/rdf-schema#label |
MK2206
|
| gptkbp:intendedUse |
gptkb:cancer
|
| gptkbp:isInvestigational |
true
|
| gptkbp:mechanismOfAction |
AKT inhibitor
|
| gptkbp:molecularWeight |
476.98 g/mol
|
| gptkbp:PubChem_CID |
25154816
CHEMBL1172569 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:studiedBy |
gptkb:cancer
prostate cancer hematologic malignancies |
| gptkbp:target |
gptkb:AKT1
gptkb:AKT2 gptkb:AKT3 |
| gptkbp:UNII |
6Z5B6HVF6O
|
| gptkbp:bfsParent |
gptkb:MK-2206
|
| gptkbp:bfsLayer |
7
|